...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Breast care >Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia
【24h】

Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia

机译：化疗引起的中性粒细胞减少或发热性中性粒细胞减少的乳腺癌患者的治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chemotherapy-induced neutropenia (CIN) is a common toxicity caused by the administration of anticancer drugs. This side effect is associated with life-threatening infections and may alter the chemotherapy schedule, thus impacting on early and long-term outcomes. Elderly breast cancer patients with impaired health status or advanced disease as well as patients undergoing dose-dense anthracycline/taxane- or docetaxel-based regimens have the highest risk of CIN. A careful assessment of the baseline risk for CIN allows the selection of patients who need primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) and/or antimicrobial agents. Neutropenic cancer patients may develop febrile neutropenia and CIN-related severe medical complications. Specific risk assessment scores, along with comprehensive clinical evaluation, are able to define a group of febrile patients with low risk for complications who can be safely treated as outpatients. Conversely, patients with higher risk of severe complications should be hospitalized and should receive intravenous antibiotic therapy with or without G-CSF.
机译：化疗引起的中性粒细胞减少症（CIN）是由抗癌药物引起的常见毒性。这种副作用与威胁生命的感染有关，并可能改变化疗方案，从而影响早期和长期结果。健康状况受损或疾病晚期的老年乳腺癌患者以及接受剂量密集的蒽环类/紫杉烷类或多西他赛类治疗的患者发生CIN的风险最高。通过仔细评估CIN的基线风险，可以选择需要主要预防粒细胞集落刺激因子（G-CSF）和/或抗菌药物的患者。中性粒细胞减少症患者可能会出现发热性中性粒细胞减少和与CIN相关的严重医学并发症。特定的风险评估评分以及全面的临床评估能够确定一组并发症风险低的发热患者，可以将其安全地视为门诊患者。相反，严重并发症风险较高的患者应住院治疗，并应接受或不伴G-CSF的静脉内抗生素治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号